915087-26-2

Basic information

• Product Name: 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE
• Synonyms: 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE;4-[(1-cyanocyclobutyl)amino]-N-methylbenzamide;ARN-509 intermediate 2
• CAS NO: 915087-26-2
• Molecular Formula: C₁₃H₁₄FN₃O
• Molecular Weight: 247.27
• Mol File: 915087-26-2.mol

Chemical Properties

• Boiling Point: 447.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.06±0.46(Predicted)
• CAS DataBase Reference: 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(915087-26-2)
• EPA Substance Registry System: 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(915087-26-2)

Safety Data

• Hazardous Substances Data: 915087-26-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE is used as a research tool for the study of potential medications for a wide range of conditions. Its unique structure and pharmacological properties contribute to the investigation of new drug candidates, aiding in the discovery of novel therapeutic agents.
Used in Medical Imaging and Diagnostic Techniques:
In the medical field, 4-(1-CYANOCYCLOBUTYLAMINO)-2-FLUORO-N-METHYLBENZAMIDE may have potential applications in imaging and diagnostic techniques. Its ability to interact with biological systems suggests that it could be utilized in the development of contrast agents or probes for visualizing specific biological processes or structures within the body.

Upstream product

• 915087-25-1 2-fluoro-N-methyl-4-amino-benzamide 
• 1191-95-3 cyclobutanone 
• 143-33-9 sodium cyanide 
• 956104-46-4 2-fluoro-4-(4-methoxybenzylamino)-N-methylbenzamide 
• 948717-18-8 2,4-difluoro-N-methylbenzamide 
• 72482-64-5 2,4-difluorobenzoyl chloride 
• 773837-37-9 sodium cyanide 
• 73792-06-0 ethyl-4-amino-2-fluorobenzoate 
• 915087-24-0 2-fluoro-N-methyl-4-nitro-benzamide 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 956104-40-8 ARN-509 
• 1272718-96-3 4-[7-(4-cyano-2,5-difluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-64-4 4-[7-(2-chloro-4-cyano-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-63-3 4-[7-(4-cyano-2-trifluoromethyl-phenyl)-8-oxo-6-thio-5,7-diazaspiro[3,4]-5-octyl]-2-fluoro-N-methyl benzamide 
• 1245736-62-2 4-[7-(4-cyano-2-methyl-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-60-0 4-[7-(4-cyano-2-trifluoromethoxy-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-97-4 4-[7-(3-chloro-4-cyano-2-fluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-42-8 4-[7-(4-cyano-3-methoxy-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-61-1 4-[7-(4-cyano-2-fluoro-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1245736-43-9 4-[7-(3,4-dicyano-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-98-5 4-[7-(4-cyano-2-fluoro-3-trifluoromethyl-phenyl)-8-oxo-6-thioxo-5,7-diaza-spiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide 
• 915087-27-3 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide 

Relevant articles and documents

Process for the preparation of 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and its polymorphs

The present application relates a process for the preparation of 4- [7 - (6-Cyano- 5- trifluoro methyl pyridin-3- yl) -8- oxo -6- thioxo- 5,7- diazaspiro [3.4] oct-5- yl]- 2-fluoro-N-methyl benzamide of formula-1. The present application further discloses a processes for the preparation of amorphous and crystalline form of compound of formula-1. Formula-1.

PROCESS FOR THE PREPARATION OF APALUTAMIDE

Aspect of the present application relates to process for the preparation of crystalline form of Apalutamide and process for the preparation of Apalutamide in the presence of neutralizing agent selected from triethylsilylchloride, trimethylsilyl chloride, zinc chloride, aluminium chloride, iron chloride, sodium chloride, acetic acid, ammonium chloride or mixture thereof followed by treating with acid to obtain Apalutamide.

SOLID STATE FORMS OF APALUTAMIDE

Disclosed are solid state forms of Apalutamide and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.

Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles

A series of deuterated apalutamide were designed and prepared. Compared to its prototype compound 18, deuterated analogues 19 and 21 showed obviously higher plasma concentrations and better PK parameters after oral administration in mice. In rats, N-trideuteromethyl compound 19 displayed 1.8-fold peak concentration (Cmax), and nearly doubled its drug exposure in plasma (AUC0–∞) compared to compound 18. Unsurprisingly, compounds 18 and 19 had similar affinity for AR in vitro. In summary, the deuteration strategy could obviously improve PK parameters of apalutamide.

Substituted diazaspiroalkanes as androgen receptor modulators

This invention provides for compounds of the Formula II: wherein A, B, Het, R1, R2 and R3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.

ANDROGEN RECEPTOR MODULATOR FOR TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES

PROBLEM TO BE SOLVED: To provide a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. SOLUTION: The present invention relates to hydantoin compounds, methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example, prostate cancer, and to pharmaceutical compositions containing such compounds. In an embodiment, a pharmaceutical composition includes a therapeutically effective amount of a compound according to the formula II, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. The present invention provides a series of compounds that modulate the function of the nuclear hormone receptors, especially the androgen receptor. These compounds can cause disappearance of prostate cancer cells and tumors. COPYRIGHT: (C)2016,JPOandINPIT

IMIDAZOLE DIKETONE COMPOUND AND USE THEREOF

Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds possess androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.

IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES

Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.

IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES

Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.